RESMED ($RMD) posted quarterly earnings results for Q3 2026 on Thursday, April 30th. The company reported earnings of $2.86 per share, beating estimates of $2.83 by $0.03. The company also reported revenue of $1,431,410,000, missing estimates of $1,433,458,155 by $-2,048,155.
Stock price change since market close: -3.44%
You can see Quiver Quantitative's $RMD stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
RESMED Insider Trading Activity
RESMED insiders have traded $RMD stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales.
Here’s a breakdown of recent trading of $RMD stock by insiders over the last 6 months:
- MICHAEL J. FARRELL (Chairman and CEO) has made 0 purchases and 6 sales selling 32,966 shares for an estimated $8,240,458.
- PETER C FARRELL has made 0 purchases and 6 sales selling 12,000 shares for an estimated $2,977,760.
- BRETT SANDERCOCK (Chief Financial Officer) has made 0 purchases and 5 sales selling 7,000 shares for an estimated $1,709,870.
- WITTE JAN DE has made 0 purchases and 2 sales selling 2,542 shares for an estimated $645,896.
- MICHAEL J RIDER (Global General Counsel) has made 0 purchases and 3 sales selling 150 shares for an estimated $37,295.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
RESMED Hedge Fund Activity
We have seen 416 institutional investors add shares of RESMED stock to their portfolio, and 450 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,790,548 shares (-76.9%) from their portfolio in Q4 2025, for an estimated $672,159,296
- FIRST TRUST ADVISORS LP added 1,072,394 shares (+240.9%) to their portfolio in Q4 2025, for an estimated $258,307,542
- DEUTSCHE BANK AG\ added 787,949 shares (+126.0%) to their portfolio in Q4 2025, for an estimated $189,793,275
- MORGAN STANLEY added 578,559 shares (+25.0%) to their portfolio in Q4 2025, for an estimated $139,357,506
- FMR LLC removed 464,493 shares (-52.8%) from their portfolio in Q4 2025, for an estimated $111,882,428
- ROYAL BANK OF CANADA removed 420,468 shares (-59.5%) from their portfolio in Q4 2025, for an estimated $101,278,127
- DIAMANT ASSET MANAGEMENT, INC. added 402,164 shares (+21166.5%) to their portfolio in Q1 2026, for an estimated $90,277,774
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
RESMED Analyst Ratings
Wall Street analysts have issued reports on $RMD in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 04/15/2026
To track analyst ratings and price targets for RESMED, check out Quiver Quantitative's $RMD forecast page.
RESMED Price Targets
Multiple analysts have issued price targets for $RMD recently. We have seen 7 analysts offer price targets for $RMD in the last 6 months, with a median target of $275.0.
Here are some recent targets:
- Brett Fishbin from Keybanc set a target price of $290.0 on 04/27/2026
- Laura Sutcliffe from Citigroup set a target price of $340.0 on 04/09/2026
- Adam Maeder from Piper Sandler set a target price of $275.0 on 01/30/2026
- Nathan Treybeck from Wells Fargo set a target price of $270.0 on 01/30/2026
- Jonathan Block from Stifel set a target price of $265.0 on 01/30/2026
- Craig Wong-Pan from RBC Capital set a target price of $314.0 on 01/30/2026
- Joe Vruwink from Baird set a target price of $275.0 on 12/16/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
